A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study

NCT05613569 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2024-07-08

No results posted yet for this study

Summary

This is a long-term, 3-year, follow-up study for patients completing the KS-GIG-001-01 Study

Conditions

  • Lumbosacral Radiculopathy

Interventions

DRUG

KLS-2031

KLS-2031 administered by transforaminal epidural injection

Sponsors & Collaborators

  • Kolon Life Science

    lead INDUSTRY

Principal Investigators

  • Todd Bertoch, MD · JBR Clinical Research

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2026-08-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05613569 on ClinicalTrials.gov